Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Betting On La Jolla Pharmaceutical Company (LJPC)

Page 1 of 2

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. The Standard and Poor’s 500 Index returned 7.6% over the 12-month period ending November 21, while more than 51% of the constituents of the index underperformed the benchmark. Hence, a random stock picking process will most likely lead to disappointment. At the same time, the 30 most favored mid-cap stocks by the best performing hedge funds monitored by Insider Monkey generated a return of 18% over the same time span. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That’s why we are going to go over recent hedge fund activity in La Jolla Pharmaceutical Company (NASDAQ:LJPC) .

Is La Jolla Pharmaceutical Company (NASDAQ:LJPC) a buy right now? Hedge funds are altogether taking a bullish view. The number of bullish hedge fund positions that are disclosed in regulatory 13F filings rose by 1 lately. There were 9 hedge funds in our database with LJPC positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Sun Bancorp, Inc. NJ (NASDAQ:SNBC), Park Sterling Bank (NASDAQ:PSTB), and Brightcove Inc (NASDAQ:BCOV) to gather more data points.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, internet, male, drugstore, service,

racorn/Shutterstock.com

Keeping this in mind, we’re going to take a gander at the latest action regarding La Jolla Pharmaceutical Company (NASDAQ:LJPC).

How are hedge funds trading La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

At Q3’s end, a total of 10 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 11% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in LJPC over the last 5 quarters. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart

When looking at the institutional investors followed by Insider Monkey, Kevin C. Tang of Tang Capital Management holds the most valuable position in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Tang Capital Management has a $75.9 million position in the stock, comprising 31.5% of its 13F portfolio. The second most bullish fund manager is Kevin Kotler of Broadfin Capital, with a $34.4 million position; the fund has 3.1% of its 13F portfolio invested in the stock. Remaining members of the smart money that hold long positions encompass Joseph Edelman’s Perceptive Advisors. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2